NO20031623L - Liposomal formulering av mitoxantron - Google Patents

Liposomal formulering av mitoxantron

Info

Publication number
NO20031623L
NO20031623L NO20031623A NO20031623A NO20031623L NO 20031623 L NO20031623 L NO 20031623L NO 20031623 A NO20031623 A NO 20031623A NO 20031623 A NO20031623 A NO 20031623A NO 20031623 L NO20031623 L NO 20031623L
Authority
NO
Norway
Prior art keywords
mitoxantrone
liposomal formulation
liposomal
formulation
Prior art date
Application number
NO20031623A
Other languages
English (en)
Other versions
NO20031623D0 (no
Inventor
Imran Ahmad
Aquilur Rahman
Original Assignee
Neopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neopharm Inc filed Critical Neopharm Inc
Publication of NO20031623D0 publication Critical patent/NO20031623D0/no
Publication of NO20031623L publication Critical patent/NO20031623L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
NO20031623A 2000-10-16 2003-04-09 Liposomal formulering av mitoxantron NO20031623L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24106900P 2000-10-16 2000-10-16
PCT/US2001/042757 WO2002032400A1 (en) 2000-10-16 2001-10-16 Liposomal formulation of mitoxantrone

Publications (2)

Publication Number Publication Date
NO20031623D0 NO20031623D0 (no) 2003-04-09
NO20031623L true NO20031623L (no) 2003-06-05

Family

ID=22909113

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20031623A NO20031623L (no) 2000-10-16 2003-04-09 Liposomal formulering av mitoxantron

Country Status (15)

Country Link
US (1) US20030219476A1 (no)
EP (1) EP1333811A4 (no)
JP (1) JP2004511510A (no)
CN (1) CN1469735A (no)
AU (1) AU2002214649A1 (no)
BR (1) BR0114713A (no)
CA (1) CA2424345A1 (no)
CZ (1) CZ20031262A3 (no)
EA (1) EA200300473A1 (no)
HU (1) HUP0303719A2 (no)
IL (1) IL155291A0 (no)
MX (1) MXPA03003401A (no)
NO (1) NO20031623L (no)
WO (1) WO2002032400A1 (no)
ZA (1) ZA200302670B (no)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
JP2004501955A (ja) * 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
PL363618A1 (en) * 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
WO2003018018A2 (en) * 2001-08-24 2003-03-06 Neopharm, Inc. Vinorelbine compositions and methods of use
JP2005508375A (ja) * 2001-11-09 2005-03-31 ネオファーム、インコーポレイティッド Ｉｌ−１３を発現する腫瘍の選択的治療
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
AU2003240934A1 (en) * 2002-05-29 2003-12-19 Neopharm, Inc. Method for determining oligonucleotide concentration
WO2004017944A1 (en) * 2002-08-23 2004-03-04 Neopharm, Inc. Liposomal gemcitabine compositions for better drug delivery
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
EA200501285A1 (ru) * 2003-02-11 2006-02-24 Неофарм, Инк. Способ получения липосомальных препаратов
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
US20060078560A1 (en) * 2003-06-23 2006-04-13 Neopharm, Inc. Method of inducing apoptosis and inhibiting cardiolipin synthesis
CA2578248A1 (en) * 2004-09-15 2006-03-23 Vasogen Ireland Limited Multiple sclerosis treatment
EP1807051A2 (en) * 2004-11-05 2007-07-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
EP3067046B1 (en) 2005-12-08 2020-03-25 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
WO2008127358A2 (en) * 2006-10-10 2008-10-23 Jina Pharmaceuticals, Inc. Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof
JP2010509355A (ja) 2006-11-06 2010-03-25 ジャイナ ファーマシューティカルズ，インコーポレーテッド グッグルリン脂質の方法および組成物
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
CN102448488B (zh) 2009-06-04 2014-10-15 独立行政法人产业技术综合研究所 支原体感染症用疫苗
CN101773471B (zh) * 2010-03-25 2012-07-11 天津大学 一种米托蒽醌纳米靶向缓释长循环脂质体及制备方法
US20130115271A1 (en) * 2010-04-19 2013-05-09 The University Of North Carolina At Chapel Hill Predictors of pharmacokinetic and pharmacodynamic disposition of carrier-mediated agents
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
SI2852391T1 (sl) 2012-05-21 2022-04-29 Insmed Incorporated Sistemi za obravnavo pljučnih infekcij
TR201908531T4 (tr) 2012-11-20 2019-08-21 Arbutus Biopharma Corp Terapöti̇k kullanim i̇çi̇n li̇pozom kapsüllü vi̇nkri̇sti̇ni̇n preparasyonuna yöneli̇k geli̇şti̇ri̇lmi̇ş yöntem
CA2891487A1 (en) 2012-11-29 2014-06-05 Insmed Incorporated Stabilized vancomycin formulations
DK3466432T3 (da) 2014-05-15 2020-09-28 Insmed Inc Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019232417A1 (en) * 2018-06-01 2019-12-05 Washington University Compounds and methods for the treatment of toxoplasma gondii infection
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
WO2021180184A1 (zh) * 2020-03-12 2021-09-16 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体的用途
CN114601791B (zh) * 2020-12-08 2023-09-19 成都倍特药业股份有限公司 一种盐酸米托蒽醌液体制剂及其制备方法
AU2021399438A1 (en) * 2020-12-15 2023-07-06 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd Use of mitoxantrone hydrochloride liposome
CN115770288A (zh) * 2021-09-07 2023-03-10 石药集团中奇制药技术（石家庄）有限公司 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820738A (en) * 1977-08-15 1989-04-11 American Cyanamid Company 1,4-bis(substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof
US4197249A (en) * 1977-08-15 1980-04-08 American Cyanamid Company 1,4-Bis(substituted-amino)-5,8-dihydroxyanthraquinones and leuco bases thereof
US4428882A (en) * 1979-05-29 1984-01-31 American Cyanamid Company 1-(Aminoalkylamino)-5,8-dihydroxy-4-substituted-anthraquinones
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
DE3360633D1 (en) * 1982-02-12 1985-10-03 Unitika Ltd Anti-cancer device
JPS60246400A (ja) * 1984-05-22 1985-12-06 Ajinomoto Co Inc アントラサイクリン系化合物及び制ガン剤
IL76002A0 (en) * 1984-08-03 1985-12-31 Boehringer Biochemia Srl Amino-anthracenediones-platinum complexes useful as anti-cancer compounds
GB8508508D0 (en) * 1985-04-01 1985-05-09 Creighton A M Pharmaceutical compositions
EP0198765A3 (en) * 1985-04-09 1987-10-21 Georgetown University Preparation of liposomes
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
IN165717B (no) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US5716829A (en) * 1987-01-15 1998-02-10 Genetic Systems Corporation Diagnostic test for Pseudomonas aeruginosa infections
MX9203808A (es) * 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5000886A (en) * 1987-05-26 1991-03-19 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules and process of making the same
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5744455A (en) * 1988-01-27 1998-04-28 New York University Reduction of anthracycline-induced cardiotoxicity
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
ATE77051T1 (de) * 1988-03-04 1992-06-15 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5831066A (en) * 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
WO1990014105A1 (en) * 1989-05-15 1990-11-29 The Liposome Company, Inc. Accumulation of drugs into liposomes by a proton gradient
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
GB9017024D0 (en) * 1990-08-03 1990-09-19 Erba Carlo Spa New linker for bioactive agents
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
JPH04334377A (ja) * 1990-12-31 1992-11-20 Akzo Nv 酸−不安定性リンカー分子
PL168202B1 (pl) * 1991-01-11 1996-01-31 Glaxo Lab Sa S posób wytwarzania nowych pochodnych akrydyny PL PL
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
US5399338A (en) * 1991-05-01 1995-03-21 University Of New Mexico Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US6017900A (en) * 1991-07-03 2000-01-25 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and nsaids
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
ATE239506T1 (de) * 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
AU3922193A (en) * 1992-03-23 1993-10-21 Georgetown University Liposome encapsulated taxol and a method of using the same
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5301688A (en) * 1992-08-07 1994-04-12 Physion S.R.L. Method for localization and therapy of occult bladder cancer
AU5092893A (en) * 1992-09-02 1994-03-29 Georgetown University Method of encapsulating anthracycline glycosides in liposomes
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.
US5378456A (en) * 1993-03-25 1995-01-03 American Cyanamid Company Antitumor mitoxantrone polymeric compositions
US5807549A (en) * 1993-05-21 1998-09-15 Research Corporation Technologies, Inc. Lymphocyte chemoattractant factor and uses thereof
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599712A (en) * 1993-10-15 1997-02-04 University Of Pittsburgh Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
IN176897B (no) * 1993-10-29 1996-09-28 Cadila Lab Ltd
GB9325330D0 (en) * 1993-12-10 1994-02-16 Univ Toronto Fluorocyclodextrin drug delivery system
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9402805D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5730968A (en) * 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
US5604090A (en) * 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5716612A (en) * 1994-09-07 1998-02-10 Schering Corporation Use of IL-4 for potentiation of chemotherapeutic agents
US5602142A (en) * 1994-12-21 1997-02-11 Evanston Hospital Corporation DNA-affinic hypoxia selective cytotoxins
DE19502912A1 (de) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
GB9509888D0 (en) * 1995-05-16 1995-07-12 Pharmacia Spa Terpenoidic derivatives useful as antitumour agents
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US6200992B1 (en) * 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
DE19538402A1 (de) * 1995-10-14 1997-04-17 Boehringer Mannheim Gmbh Lipidalkohole als neue immunsuppressive und antivirale Arzneimittel
WO1997034612A1 (en) * 1996-03-22 1997-09-25 Waldemar Priebe Bis-anthracyclines with high activity against doxorubicin resistant tumors
US5672592A (en) * 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5863536A (en) * 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US6025345A (en) * 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US6197295B1 (en) * 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6339069B1 (en) * 1996-10-15 2002-01-15 Elan Pharmaceuticalstechnologies, Inc. Peptide-lipid conjugates, liposomes and lipsomal drug delivery
US6177404B1 (en) * 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US6037454A (en) * 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6207673B1 (en) * 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US6180666B1 (en) * 1997-09-05 2001-01-30 Anmax, Inc. Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds
US6020316A (en) * 1997-09-25 2000-02-01 Lanks; Karl W. Glutaraldehyde modified chemotherapeutic agents and methods of use thereof
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
JP2001526033A (ja) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド ヒトインターフェロン−イプシロンというｉ型インターフェロン
US6030997A (en) * 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
AU4232199A (en) * 1998-06-05 1999-12-20 Board Of Regents, The University Of Texas System Texaphyrin conjugates and uses thereof
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
DE69900689T2 (de) * 1998-06-26 2002-08-29 Quanam Medical Corp Topoisomerase inhibitoren zur restenose-prevention
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
EP1006113A1 (en) * 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6174903B1 (en) * 1998-12-28 2001-01-16 Pfizer Inc. Imidazolidin-4-one derivatives useful as anticancer agents
US6200599B1 (en) * 1999-10-07 2001-03-13 The Regents Of The University Of California Ortho ester lipids
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
US20020004070A1 (en) * 2000-02-24 2002-01-10 Rudnic Edward M. Antineoplastic product, use and formulation thereof
US7405080B2 (en) * 2000-03-23 2008-07-29 Voellmy Richard W Compositions and methods relating to prevention of chemotherapy-induced alopecia
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
NZ521540A (en) * 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
JP4763957B2 (ja) * 2000-05-10 2011-08-31 オバン・エナジー・リミテッド メディアミリング
US6733764B2 (en) * 2000-06-14 2004-05-11 Alain Martin Immunostimulator anti-cancer compounds and methods for their use in the treatment of cancer
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions

Also Published As

Publication number Publication date
CZ20031262A3 (en) 2004-03-17
ZA200302670B (en) 2004-07-05
IL155291A0 (en) 2003-11-23
MXPA03003401A (es) 2004-06-30
CA2424345A1 (en) 2002-04-25
NO20031623D0 (no) 2003-04-09
AU2002214649A1 (en) 2002-04-29
EP1333811A4 (en) 2004-03-03
EP1333811A1 (en) 2003-08-13
WO2002032400A1 (en) 2002-04-25
US20030219476A1 (en) 2003-11-27
HUP0303719A2 (hu) 2004-03-01
CN1469735A (zh) 2004-01-21
BR0114713A (pt) 2004-01-13
EA200300473A1 (ru) 2003-08-28
JP2004511510A (ja) 2004-04-15

Similar Documents

Publication Publication Date Title
NO20031623L (no) Liposomal formulering av mitoxantron
ID30590A (id) Celana sekali pakai jenis-celana pendek
DE60020518D1 (de) Verwaltung von Benutzerprofilen
NO20030134L (no) Fremstilling av olefinderivater
ITTO20010008A0 (it) Formulazione farmaceutica
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
AR028291A1 (es) Formulaciones oftalmicas
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
NO20030030D0 (no) Farmasöytiske blandinger av östrogene midler
DE60024988D1 (de) Herstellung von therapeutischem mikroschaum
AR026045A1 (es) Formulaciones de liberacion prolongada de derivados de eritromocina
EE200200393A (et) Glüburiidi ravimkoostis
ID30187A (id) Dongkrak jenis pantagraf
ID30226A (id) Komposisi penat rambut
DE60132362D1 (de) Herstellung von ultradünnwandigen cordierit-strukturen
DE60142051D1 (de) Herstellung von perfluorolefinen
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
NO20021730L (no) Ny formulering av mirtazapin
NO20023785L (no) Vanndispergerbar formulering av paroxetin
PT1272470E (pt) Forma modificada da torasemida amorfa
NO20003799D0 (no) Innkorporering av kolesterol-senkende midler i konfektdosisformer
EE200300434A (et) Farmatseutiliselt toimivate ühendite kasutamine
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
DE60117846D1 (de) Herstellung von 6-aminocaprinsäurealkylestern
ITMI20011820A0 (it) Trattamento di ustioni

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application